

**Second Asia Summit on Global Health Opens Today****Haitong International bridges healthcare industry development and investment opportunities**

**Hong Kong, 10 November 2022** - The second Asia Summit on Global Health (ASGH) co-organized by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC) opened today at the Hong Kong Convention and Exhibition Centre (HKCEC). Themed "Charting a New Course in Healthcare through Collaboration", the summit brought together over 80 speakers including healthcare officials and organizations from around the world, international science and medical experts, investors, key industry players, business leaders, financial specialists and professional service providers. **Haitong International Securities Group ("Haitong International" or the Group; 665.HK), the Strategic Partner of the Summit**, and its corporate clients were invited to participate in the panel discussions. Haitong International and HKTDC also jointly released an industry research report on the healthcare sector.

**Mr John Lee, Chief Executive of the HKSAR, Mr Cao Xuetao, Vice-Minister of National Health Commission of the PRC, Dr Zsuzsanna Jakab, Deputy Director-General of World Health Organization and Ms Margaret Fong, Executive Director of HKTDC**, attended the Summit's opening session. In the opening remarks, Mr John Lee, Chief Executive of the HKSAR, said "Hong Kong stays on top in health and other areas, with prominent universities and technological infrastructures; and is the world's leading fundraising hub for biotech companies. Public health and innovative technology are at the heart of Hong Kong's policy priorities, and the government will continue to develop the innovation and technology ecosystem and research talent hub, building Hong Kong into a world class smart city and integrating the city into the national development."

**In-depth discussions on industry development and opportunities**

The Summit featured a number of panel discussions on the first day, covering topics including the next developments in China's healthcare sector, how innovation reshapes global healthcare, and Hong Kong as a fundraising hub for global biotechnology and healthcare. A number of government officials, representatives from regulatory bodies and the medical industry, including **Prof Chung-mau Lo, Secretary for Health of the HKSAR, Prof Dong Sun, Secretary for Innovation, Technology and Industry of the HKSAR, Prof Ruilin Song, Executive President of China Pharmaceutical Innovation and Research Development Association, Mr Nicolas Aguzin, Chief Executive Officer of Hong Kong Exchanges and Clearing Limited and Prof Thomas Herget, Head of Merck China Innovation Hub**, participated in the discussion.

**Mr Henry Shi, Executive Committee Member of Haitong International**, attended the first day of the

Summit and said "Hong Kong is a world-leading financing hub for global biotechnology, and the government is committed to strengthening Hong Kong's strategic role as an innovation and investment hub for Asia's healthcare industry. Haitong International, a Chinese investment bank with strong presence in Hong Kong, will actively ride on its expertise in investment, financing and research in the healthcare sector to connect potential companies with overseas markets and investment opportunities, promoting Hong Kong's new positioning as an international innovation and technology hub as outlined in the 14<sup>th</sup> Five-year Plan."

**Ms Wenxin Yu, Principal Analyst of Pharmaceutical Industry and Managing Director of Haitong International**, was invited to be the speaker for the panel discussion titled "The Next Development of China's Healthcare Sector". Discussing the future development trends and prospects of the market with experts and business leaders from the medical and healthcare industry, she said, "Given the complexity of the healthcare sector, it is of utmost importance to chart the right course in the blooming prospects of the industry. In the next decade, against the backdrop of economic growth, technological iteration and internationalization opportunities, it will facilitate industry expansion and see a promising future in the areas like innovation-driven pharmaceuticals and devices, brand-driven Chinese medicine and medical services, as well as Contract X Organizations (CXOs) benefiting from industry growth. Leveraging Hong Kong's advantages in capital, technology and internationalization, it will accelerate the growth of the whole industry while complementing the nation's development."

#### **Joint research report on future opportunities of healthcare industry**

Haitong International's equity research team and HKTDC Research jointly released the "Future Prospects of Healthcare Industry in Mainland China and Hong Kong" research report in the afternoon of the first day of the Summit, which attracted extensive attention and enquiries from industry players, investors and media.

The report reviews the development of the healthcare sector in China over the past decade by providing a comprehensive analysis on the medical policy and industry structure, industry development status, as well as the demand for medical and healthcare. The Chinese pharmaceutical industry has experienced rapid growth and is moving towards the stage of innovation and internationalization. There is also long-term synergy between the expenditure of Basic Medical Insurance and the revenue from pharmaceutical manufacturing. The report explores the prospects of the healthcare industry in terms of innovation-driven and brand-driven opportunities as well as related beneficiary industries, which are expected to record double-digit growth in the next three years. Against the backdrop of Hong Kong's strategic position as an investment and financing center and an important window to the world, the development of the healthcare industry in China and Hong Kong can complement each other's strengths to build Hong Kong as a medical and healthcare hub in Asia.

**Ms Irina Fan, Director of Research of HKTDC** said "HKTDC Research is pleased to publish the joint



research report with Haitong International. Hong Kong and the Mainland have a strong complementarity in the development of the healthcare industry. While China's healthcare industry is in the acceleration process of technological innovation, Hong Kong has capabilities in quickly introducing of advanced technologies and pharmaceutical products, a capital pool in financing healthcare companies and the worldwide reputation of its clinical trials and the data obtained. Such advantages will facilitate the export of mainland products and the healthcare industry as a whole. All of these factors will promote Hong Kong to the leading healthcare hub in Asia."

To download the full report of "Future Prospects of Healthcare Industry in Mainland China and Hong Kong", please visit: <https://www.asiasummitglobalhealth.com/conference/asgh/en/joint-research-paper>

In addition, Haitong International has set up a business lounge at the Summit to connect healthcare companies with international investors and facilitate business networking and expansion. On the second day of the Summit, a number of exciting online seminars will be organized, including "Biomedical Tech Partnership for New Business Growth" and "An Expert Look into the Business of Healthcare Robotics", amongst others.

- END -

#### **Disclaimer**

We, Haitong International Securities Group Limited ("Haitong International" or "HTI") have prepared this document/presentation ("Document") for information purpose only and for restricted circulation. We have based this Document on our internal information and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this Document, we do not represent the information contained in this Document is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this Document.

Opinions, projections and estimates reflect our assessments as of the Document date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this Document. Neither we nor any of our affiliates or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this Document. This Document does not create any legally binding obligations on us and/or our affiliates.

Nothing contained in this Document is intended to constitute legal, tax, securities or investment advice of any product. No information contained in this Document constitutes an offer, or a solicitation to buy or sell any product of any type or to engage in any other transaction. You should not act or refrain from acting on the basis of any content included in this Document without seeking your own professional or investment advice. This disclaimer is available in both English and Chinese, if there is any discrepancy between the two versions, the English version shall apply and prevail.

#### **Haitong International Securities Group Limited**

Haitong International Securities Group Limited ("Haitong International"; Stock Code: 665.HK) is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. The parent company of Haitong International is Haitong Securities Co. Ltd ("Haitong Securities", Stock Code: 600837.SH; 6837.HK).

Haitong International is well positioned to serve corporate, institutional, as well as high-net worth clients worldwide. Its well-established financial services platform provides a full spectrum of financial offerings including private wealth management, corporate finance, asset management and global markets (key businesses include sales



and trading of both equity and fixed income products, prime brokerage and risk management solutions, and research advisory) businesses. Haitong International possesses a sound risk management system that is in line with international standards. The company has been assigned a "Baa2" long-term issuer rating by Moody's and a "BBB" long-term credit rating by Standard and Poor's. Haitong International is also a high performer in terms of ESG and corporate governance. It has been assigned "A" in ESG rating by MSCI and included in the FTSE4Good Index by FTSE Russell. Haitong International has a global financial servicing network covering the world's major capital markets including Hong Kong, Singapore, New York, London, Tokyo, Mumbai and Sydney, thereby making it a world-class Chinese financial institution with international competitiveness, systemic importance and brand influence.

For further information, please contact:

**Haitong International Securities Group Limited**

Judith Yu

Tel: (852) 2213 8570

Email: [judith.x.yu@htisec.com](mailto:judith.x.yu@htisec.com)

Jessica Au

Tel: (852) 2213 8588

Email: [jessica.sk.au@htisec.com](mailto:jessica.sk.au@htisec.com)

Ginny Kung

Tel: (852) 2213 8586

Email: [ginny.wy.kung@htisec.com](mailto:ginny.wy.kung@htisec.com)